On April 29, 2016 AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience reported financial results for the first quarter ended March 31, 2015 (Press release, AstraZeneca, APR 29, 2016, View Source [SID:1234511729]). Schedule your 30 min Free 1stOncology Demo! Total worldwide product sales for the first quarter of 2016 was $ 5,565 million USD in comparison to that of $5,748 million USD for the first quarter of 2015. Total oncology product sales increased from $ 674 million USD in the first of 2015 to $738 million USD in the first quarter of 2016.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Regional sales for the first quarter of 2016 equated to; US – $2,169 m USD, Europe -$1,340 m USD, Established ROW- $706 m USD and Emerging markets – $1,533 m USD. Total regional sales of oncology products were; US- $106 m USD, Europe – $158 m USD, Established ROW – $170 m USD and $240 m USD in Emerging Markets.
For AstraZeneca’s detailed sales figures, visit: View Source
View Source